Premium
Short‐term growth in children with eczema during treatment with topical mometasone furoate and tacrolimus
Author(s) -
Gradman Josefine,
Wolthers Ole D
Publication year - 2007
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.2007.00363.x
Subject(s) - mometasone furoate , medicine , tacrolimus , atopic dermatitis , adverse effect , dermatology , crossover study , corticosteroid , pediatrics , transplantation , alternative medicine , pathology , placebo
Background: Treatment with topical glucocorticoids in children with atopic eczema may be associated with systemic adverse effects, such as suppression of growth. Aim: To asses if treatment with topical mometasone furoate 0.1% or topical tacrolimus 0.1% affects short‐term growth in children with atopic eczema. Primary outcome measures were lower leg growth rates measured by knemometry. Methods: Twenty 5‐ to 12‐year‐old prepubertal children with atopic eczema were included in a randomised, investigator‐blind crossover study with five periods: two treatment periods, a run in, a wash out and a run out. All periods were of 2‐week duration. The subjects applied mometasone furoate ointment 0.1% once daily during one treatment period and tacrolimus ointment 0.1% twice daily during the other treatment period. Results: As compared to run in mean lower leg growth rate during mometasone furoate and tacrolimus treatment was reduced by 0.09 and 0.06 mm/week, respectively, (F = 1.12, p = 0.35). Consistently, no statistically significant effects on urine levels of eosinophil protein X and crossed‐linked N‐telopeptides were detected. Conclusion: Treatment with mometasone furoate or tacrolimus does not affect short‐term growth in children with mild to moderate atopic eczema.